Daily Health Headlines

New Biologic Drug Tackles Hard-to-Control Asthma

👤by Steven Reinberg 0 comments 🕔Wednesday, September 7th, 2016

WEDNESDAY, Sept. 7, 2016 (HealthDay News) -- A new injectable drug reduces flare-ups in patients with severe asthma that is not controlled by steroid inhalers alone, two new trials show.

The drug, benralizumab, is a biologic that works by killing white blood cells called eosinophils. These are present in large numbers in such patients, and they have been linked to severe asthma.

If approved by the U.S. Food and Drug Administration, benralizumab would join two similar drugs -- mepolizumab (Nucala) and reslizumab (Cinqair) -- in fighting hard-to-control asthma, the researchers said.

"We can offer patients who frequently require courses of oral corticosteroids and have a certain level of eosinophils [an allergy-related cell easily measured in the blood] a very effective treatment," said study author Dr. J. Mark FitzGerald. He is a professor of respiratory health at the University of British Columbia in Vancouver.

"With the right patient with the right characteristics, we can significantly modify the level of asthma severity," added FitzGerald, who had a hand in both trials.

The studies were funded by AstraZeneca, the maker of benralizumab, and published online Sept. 5 in The Lancet, to coincide with the presentation of the findings at the European Respiratory Society meeting in London.

FitzGerald reports serving as a consultant to AstraZeneca.

One potential advantage of benralizumab is that it can be given less often, said Dr. Mario Castro, a professor of medicine and pediatrics at Washington University School of Medicine in St. Louis.

"The treatments that we have now are done every two weeks or once a month, but benralizumab can be given every two months, which may lower the cost," he said.

The available drugs cost about $25,000 to $30,000 a year and are covered by insurance, including Medicare, said Castro, who co-authored an editorial accompanying the trial reports.

The current drugs have been approved for patients aged 12 and older, "but we are very interested in them moving to the next lower age range of 6 and above," he said.

"If you have severe asthma and you're not getting the control that you need, ask your doctor about these medications," Castro suggested.

In the first trial, more than 1,300 patients aged 12 to 75 were randomly assigned to one of three groups: benralizumab given every four weeks; benralizumab given every eight weeks; or a placebo. In addition, the patients continued to use high-dose inhaled corticosteroids and long-acting beta agonists inhalers to control their asthma.

Over 52 weeks, the researchers found that patients taking benralizumab had a 28 percent to 36 percent reduction in flare-ups, compared with a placebo. Patients on benralizumab also showed improved lung function.

The most common side effects were cold-like symptoms in 20 percent of those receiving benralizumab, versus 21 percent of those on a placebo, and worsening asthma, 12 percent versus 15 percent, respectively.

Four patients suffered from serious side effects, including one case of hives and two cases of herpes. One patient who was taking a placebo suffered chest pains. Because of side effects, seven patients receiving benralizumab and three receiving a placebo dropped out of the trial.

"About 10 percent of patients with asthma have severe disease, which flares in spite of current maximal therapies," said Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City.

Compared with Nucala and Cinqair, benralizumab appears to work in a different way by reducing the number of eosinophils, cells that cause asthma, he said.

"Immune modulation has been on the forefront in treating many diseases, including cancer, but this drug represents a step forward in treating asthma," Horovitz said.

In the second trial, more than 1,200 patients were assigned to similar groups as in the first trial. The researchers found that benralizumab cut asthma flare-ups by 45 percent to 51 percent, compared with a placebo.

The most common side effects were worsening asthma in 13 percent of those receiving benralizumab, compared to 12 percent of those receiving a placebo, and cold-like symptoms experienced by 12 percent of patients in both groups.

Among patients taking benralizumab, four suffered serious side effects. One patient had allergic granulomatous (inflammation of blood vessels), one patient had a panic attack and one had paresthesia (pins and needles). Among those receiving the placebo, one had a skin reaction at the site of the injection. In all, 18 patients receiving benralizumab and three receiving a placebo dropped out of the study due to side effects, the researchers said.

One respiratory disease expert sees this new drug as another breakthrough in treating hard-to-control asthma.

"These biologicals treat patients that were previously untreatable, and these treatments are getting better and better," said Dr. Alan Mensch, chief of pulmonary medicine at Northwell Health's Plainview Hospital in New York.

Article Credits / Source

Steven Reinberg / HealthDay

Steven Reinberg wrote this story for HealthDay. HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCES: J. Mark FitzGerald, M.D., professor, respiratory health, University of British Columbia, Vancouver, Canada; Len Horovitz, M.D. pulmonary specialist, Lenox Hill Hospital, New York City; Mario Castro, M.D., professor, medicine and pediatrics, Washington University School of Medicine, St. Louis; Alan Mensch, M.D., chief, pulmonary medicine, Northwell Health's Plainview Hospital, Plainview, N.Y.; Sept. 5, 2016, The Lancet, online

View More Articles From Steven Reinberg 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More Asthma Articles

ephedrine (oral)

ephedrine (oral)0

home / asthma center / asthma a-z list / ephedrine-oral index / ephedrine (oral) drug monograph Pharmacy Author: Omudhome Ogbru, PharmD Omudhome Ogbru, PharmDDr. Ogbru received his Doctorate in ...

Advair Diskus, Advair HFA (fluticasone and salmeterol oral inhaler)

Advair Diskus, Advair HFA (fluticasone and salmeterol oral inhaler)0

home / asthma center / asthma a-z list / fluticasone and salmeterol oral inhaler index / advair diskus, advair hfa (fluticasone and salmeterol oral inhaler) drug monograph Pharmacy Author: Omudhome ...

Occupational Asthma

Occupational Asthma0

Wheezing is a whistling sound that occurs during breathing, usually during expiration (breathing air out of the lungs) through narrowed airways. Inflammation of the airways, bronchospasm (tightening of the muscles around the bronchial tubes), and ...

Clean Home May Help Keep Kids' Asthma in Check

Clean Home May Help Keep Kids' Asthma in Check0

MONDAY, Oct. 31, 2016 (HealthDay News) -- Reducing indoor allergens and pollutants can help control children's asthma, reducing their need for medication, according to a new report from the American Academy of Pediatrics. Many things in the ...

Asthma Medications

Asthma Medications0

Childhood Asthma Treatment There is often concern about potential long-term side effects for even inhaled corticosteroids. Numerous studies have repeatedly shown that even long-term use of inhaled corticosteroids has very few if any sustained ...

View More Asthma Articles

0 Comments

Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!